Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01887886 · ClinicalTrials.gov registry record · Phase 3

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

A Phase 3 study of Non-squamous Non-small Cell Lung Cancer, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 3
Development phase
10
Enrollment target
20
Study locations

NCT01887886 is a Phase 3 study of Non-squamous Non-small Cell Lung Cancer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 10 participants, below the 402-participant average among 7 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01887886, a Phase 3 study of Non-squamous Non-small Cell Lung Cancer, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 3
Development phase
10 participants
Enrollment target
20
Study locations

Study Summary

This multicenter, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of onartuzumab in combination with erlotinib in patients with previously untreated, unresectable stage IIIB or IV non-small cell lung cancer identified to carry and activating EGFR mutation and MET-positive. Patients will be randomized to receive either onartuzumab 15 mg/kg intravenously every 3 weeks in combination with erlotinib 150 mg orally daily or placebo in combination with erlotinib. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

Conditions Studied

Non-squamous Non-small Cell Lung Cancer

Interventions

  • DRUG placebo
  • DRUG erlotinib
  • DRUG onartuzumab

Study Locations (20)

California

  • - Bakersfield
  • - Fullerton
  • - Long Beach
  • - Los Angeles
  • - Los Angeles
  • - San Luis Obispo

Other

  • - Caen
  • - Lyon
  • - Nantes
  • - Großhansdorf
  • - Oldenburg

Florida

  • - Fort Myers
  • - Orlando
  • - St. Petersburg

Louisiana

  • - Marrero
  • - Metairie

Illinois

  • - Chicago

Missouri

  • - St Louis

Ohio

  • - Canton

Tennessee

  • - Nashville

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2013-12
Est. Completion 2015-02
Phase Phase 3

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01887886

The ClinicalTrials.gov registry entry for NCT01887886 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 402-participant average among 7 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-squamous Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT01887886 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Other, Florida.

Frequently Asked Questions

What is clinical trial NCT01887886 about?

NCT01887886 is a clinical study titled "A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation". This multicenter, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of onartuzumab in combination with erlotinib in patients with previously untreated, unresectable stage IIIB or IV non-small cell lung cancer identified to carry and activating EGFR mutation and...

What is the current status of trial NCT01887886?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2013-12. Estimated completion is 2015-02.

What conditions does trial NCT01887886 study?

This clinical trial studies the following conditions: Non-squamous Non-small Cell Lung Cancer.

What interventions are being tested in trial NCT01887886?

The interventions under investigation include: placebo (DRUG), erlotinib (DRUG), onartuzumab (DRUG).

Who is sponsoring clinical trial NCT01887886?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01887886 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Louisiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-squamous Non-small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-squamous Non-small Cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.